KOC
BIO icon

Koss-Olinger Consulting’s Bio-Rad Laboratories Class A BIO Stock Holding History

Koss-Olinger Consulting’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,440
Closed -$959K – 183
2026
Q1 		$959K Sell
3,440
-48
-1% -$13.8K 0.08% 99
2025
Q4 		$1.06M Sell
3,488
-2,563
-42% -$800K 0.08% 92
2025
Q3 		$1.46M Sell
6,051
-9
-0.1% -$2.45K 0.12% 101
2025
Q2 		$1.46M Sell
6,060
-88
-1% -$20.8K 0.12% 100
2025
Q1 		$1.5M Buy
+6,148
New +$1.85M 0.13% 95

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Koss-Olinger Consulting's BIO Position: Q2 2026 in Review

Koss-Olinger Consulting sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2026, closing a stake of 3,440 shares — an estimated $959K sold.

Koss-Olinger Consulting first reported a position in BIO in Q1 2025 and held it in 5 quarters. The position peaked at $1.5M in Q1 2025. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Koss-Olinger Consulting reported no remaining Bio-Rad Laboratories Class A position as of Q2 2026 after selling out during the quarter.
  • Koss-Olinger Consulting sold 3,440 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $959K.
  • Koss-Olinger Consulting first reported a position in Bio-Rad Laboratories Class A in Q1 2025 and held it in 5 quarters.
  • Koss-Olinger Consulting's Bio-Rad Laboratories Class A position peaked at $1.5M in Q1 2025.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Koss-Olinger Consulting's 13F filing for Q2 2026, filed 10 Aug 2026.